BioCentury
ARTICLE | Clinical News

Zevalin ibritumomab tiuxetan regulatory update

August 1, 2005 7:00 AM UTC

Centers for Medicare & Medicaid Services (CMS) will not draft a national coverage determination for the radiolabeled antibody Zevalin. Zevalin is marketed for non-Hodgkin's lymphoma (NHL). CMS will ma...